InSite Vision (ISV) And Senju Pharmaceutical Co., Ltd. Announce Collaboration To Develop And Commercialize Azithromycin Ophthalmic Solution Using Durasite® In Japan
6/10/2014 10:03:16 AM
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:INSV) and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite’s azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.
Help employers find you! Check out all the jobs and post your resume.
comments powered by